![](http://investorshub.advfn.com/images/default_ih_profile2_4848.jpg?cb=0)
Saturday, May 23, 2015 6:39:26 AM
Dr. Pierce's goal from the beginning was a Combo IL12+Keytruda via EP treatment. $ONCS's 1200 to 1400 watts EP opens up the cancer's protective walls forcing immunogenicity factors to enter and transmit messengers back to one's body central control that then send out NK cells to destroy cancer the enemy.
$ONCS EP+IL12 is a producer of CD8 TILs, immunogenicity biologic component. The EP would also increase the penetration of Keytruda. Thereby the immunogenicty factors working in synchronous harmony producing more NKs resulting in increased ORR destroying more cancer than either IL12 or Keytruda alone. For Dr. Pierce a dream fruition materializing.
Recent ONCSQ News
- Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] • Edgar (US Regulatory) • 02/13/2024 07:30:19 PM
North Bay Resources Announces Composite Assays of 0.53 and 0.44 Troy Ounces per Ton Gold in Trenches B + C at Fran Gold, British Columbia • NBRI • Jun 18, 2024 9:18 AM
VAYK Assembling New Management Team for $64 Billion Domestic Market • VAYK • Jun 18, 2024 9:00 AM
Fifty 1 Labs, Inc Announces Acquisition of Drago Knives, LLC • CAFI • Jun 18, 2024 8:45 AM
Hydromer Announces Attainment of ISO 13485 Certification • HYDI • Jun 17, 2024 9:22 AM
ECGI Holdings Announces LOI to Acquire Pacific Saddlery to Capitalize on $12.72 Billion Market Potential • ECGI • Jun 13, 2024 9:50 AM
Fifty 1 Labs, Inc. Announces Major Strategic Advancements and Shareholder Updates • CAFI • Jun 13, 2024 8:45 AM